CPT-11 activates NLRP3 inflammasome through JNK and NF-κB signalings.

[1]  T. Gruenberger,et al.  Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases , 2015, The Pharmacogenomics Journal.

[2]  D. Jäger,et al.  Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma , 2015, British Journal of Cancer.

[3]  Lieping Chen,et al.  Intermittent chemotherapy can retain the therapeutic potential of anti-CD137 antibody during the late tumor-bearing state , 2014, Cancer science.

[4]  Zhou Liu,et al.  Serum IL-17 and IL-6 increased accompany with TGF-β and IL-13 respectively in ulcerative colitis patients. , 2014, International journal of clinical and experimental medicine.

[5]  U. Nielsen,et al.  Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion. , 2014, Cancer research.

[6]  You Sun Kim,et al.  Colon Cancer Screening and Surveillance in Inflammatory Bowel Disease , 2014, Clinical endoscopy.

[7]  K. Breckpot,et al.  A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice , 2014, Oncotarget.

[8]  S. Palaniappan,et al.  Inflammatory Bowel Disease-related Colorectal Cancer in the Asia-Pacific Region: Past, Present, and Future , 2014, Intestinal research.

[9]  B. Chauffert,et al.  Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC , 2013, European journal of cancer.

[10]  Burkhard Becher,et al.  IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4+ Th17 cells , 2012, The Journal of experimental medicine.

[11]  Jae-Hyun Park,et al.  Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. , 2012, Cancer cell.

[12]  K. Fitzgerald,et al.  Regulation of inflammasome signaling , 2012, Nature Immunology.

[13]  A. Causse,et al.  Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma. , 2011, Cancer research.

[14]  H. Herfarth,et al.  The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer , 2010, The Journal of experimental medicine.

[15]  J. Tschopp,et al.  Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome , 2010, Gut.

[16]  M. Kastan,et al.  The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. , 2010, Immunity.

[17]  B. Siegmund.  Interleukin-18 in intestinal inflammation: friend and foe? , 2010, Immunity.

[18]  Edward Chu,et al.  A history of cancer chemotherapy. , 2008, Cancer research.

[19]  J. Bjorge,et al.  PTP1B contributes to the oncogenic properties of colon cancer cells through Src activation. , 2007, Cancer research.

[20]  Y. Pommier.  Topoisomerase I inhibitors: camptothecins and beyond , 2006, Nature Reviews Cancer.

[21]  B. Robinson,et al.  Immunotherapy and chemotherapy — a practical partnership , 2005, Nature Reviews Cancer.

[22]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[23]  J. Ajani,et al.  Therapeutic Response to Octreotide in Patients with Refractory CPT-11 Induced Diarrhea , 2001, Investigational New Drugs.

[24]  T. Yokokura,et al.  Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion , 2003, Cancer Chemotherapy and Pharmacology.

[25]  L. Saltz,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.

[26]  T. Loeffler,et al.  Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  A. Benson,et al.  Recommended guidelines for the treatment of chemotherapy-induced diarrhea. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Kumar,et al.  Prevention of intestinal toxic effects and intensification of irinotecan's therapeutic efficacy against murine colon cancer liver metastases by oral administration of the lipopeptide JBT 3002. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  G. Giaccone,et al.  Determinants of CPT-11 and SN-38 activities in human lung cancer cells. , 1998, British Journal of Cancer.

[30]  A. Akabayashi.  Questions raised over release of side-effects data in Japan , 1997, The Lancet.

[31]  S. Culine,et al.  Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  D. V. Von Hoff,et al.  Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  P. Hérait,et al.  CPT-11-induced cholinergic effects in cancer patients. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Y. Mahida,et al.  Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease. , 1989, Gut.